News

PipelineReview.com2h
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
PARIS, France I July 25, 2025 I Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, ...
PipelineReview.com2h
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
SCHLIEREN / ZURICH, Switzerland I July 25, 2025 I Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior ...
PipelineReview.com2h
GNT Pharma Receives Regulatory Approval to Initiate Multinational Phase 3 Clinical Trials for its Breakthrough Stroke Therapy ‘ Nelonemdaz™
NEW YORK, NY, USA I July 24, 2025 I GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND ...
PipelineReview.com1h
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with ...
PipelineReview.com2h
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, France I July 24, 2025 I Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable ...
PipelineReview.com1h
Novavax’s H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
GAITHERSBURG, MD, USA I July 24, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic ...
PipelineReview.com1h
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), ...
PipelineReview.com19h
Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment
STUTTGART, Germany I July 24, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor ...